Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | NT5E | P21589 | 1/20 | 0.75 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.75 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.73 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.73 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.69 |
| ▸ | DPP4 | P27487 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25756712 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL7932653 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL259446 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL6725190 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL14131245 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL24146779 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL13461111 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL10040218 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL278293 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL6934755 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120195827-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | GILEAD SCIENCE, INC. | 2012-08-02 | — | — | US | disclosed |
| US-8183226-B2 | Myocardial perfusion imaging method | GILEAD SCIENCES, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8133879-B2 | Myocardial perfusion imaging methods and compositions | GILEAD SCIENCES, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110144320-A1 | N-PYRAZOLE A2A RECEPTOR AGONISTS | GILEAD PALO ALTO, INC. | 2011-06-16 | — | — | US | disclosed |
| US-20100272645-A1 | MYOCARDIAL PERFUSION IMAGING METHOD | GILEAD PALO ALTO, INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100183503-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | GILEAD PALO ALTO, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100160620-A1 | N-PYRAZOLE A2A RECEPTOR AGONISTS | GILEAD PALO ALTO, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100081810-A1 | C-Pyrazole A2A Receptor Agonists | CV THERAPEUTICS, INC. | 2010-04-01 | — | — | US | disclosed |
| US-20100081810-A1 | C-Pyrazole A2A Receptor Agonists | CV THERAPEUTICS, INC. | 2010-04-01 | — | — | US | disclosed |
| US-7683037-B2 | A2A receptor agonist; regadenoson (CVT-3146); produces coronary vasodilation without significant peripheral vasodilation; | GILEAD PALO ALTO, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7655637-B2 | N-pyrazole A2A receptor agonists | GILEAD PALO ALTO, INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655637-B2 | N-pyrazole A2A receptor agonists | GILEAD PALO ALTO, INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-7553823-B2 | C-pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20090081120-A1 | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods | CV THERAPEUTICS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20080213165-A1 | Methods and Compositions for Increasing Patent Tolerability During Myocardial Imaging Methods | CV THERAPEUTICS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080170990-A1 | Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease | CV THERAPEUTICS, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-20070203090-A1 | N-pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20060052332-A1 | N-pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. | 2006-03-09 | — | — | US | disclosed |
| US-6642210-B1 | Administering compound to mammal by intravenous bolus injection to stress heart and induce coronary steal situation, stimulating coronary vasodilation, in order to image heart | CV THERAPEUTICS, INC. | 2003-11-04 | — | — | US | disclosed |
| US-6642210-B1 | Administering compound to mammal by intravenous bolus injection to stress heart and induce coronary steal situation, stimulating coronary vasodilation, in order to image heart | CV THERAPEUTICS, INC. | 2003-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183503-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885LMNA 1298/4885NT5E 123/4885 |
| US-20100272645-A1 | MYOCARDIAL PERFUSION IMAGING METHOD | ADORA2A, ADORA3, ADORA2B | ADORA3 2/4885LMNA 2390/4885NT5E 31/4885 |
| US-20060052332-A1 | N-pyrazole A2A receptor agonists | ADORA2A, ADORA3, TBXA2R | ADORA3 2/4885LMNA 3247/4885NT5E 115/4885 |
| US-20110144320-A1 | N-PYRAZOLE A2A RECEPTOR AGONISTS | ADORA2A, ADORA3, TBXA2R | ADORA3 2/4885LMNA 3247/4885NT5E 115/4885 |
| US-20080213165-A1 | Methods and Compositions for Increasing Patent Tolerability During Myocardial Imaging Methods | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885LMNA 1087/4885NT5E 139/4885 |
| US-20100160620-A1 | N-PYRAZOLE A2A RECEPTOR AGONISTS | ADORA2A, ADORA3, TBXA2R | ADORA3 2/4885LMNA 3247/4885NT5E 115/4885 |
| US-20080170990-A1 | Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease | ADORA2A, ADORA3, ADRB3 | ADORA3 2/4885LMNA 1171/4885NT5E 56/4885 |
| US-20090081120-A1 | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods | ADORA2A, FABP3, ADORA3 | ADORA3 3/4885LMNA 785/4885NT5E 111/4885 |
| US-20100081810-A1 | C-Pyrazole A2A Receptor Agonists | ADORA2A, ADORA3, TBXA2R | ADORA3 2/4885LMNA 2553/4885NT5E 381/4885 |
| US-20120195827-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885LMNA 1298/4885NT5E 123/4885 |
| US-20070203090-A1 | N-pyrazole A2A receptor agonists | ADORA2A, ADORA3, TBXA2R | ADORA3 2/4885LMNA 3247/4885NT5E 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.